A multicentre, open, uncontrolled phase IIIb study to evaluate the efficacy and safety of Etanercept 0.8 mg/kg body weight (bw) given once weekly to patients with polyarticular-course juvenile idiopathic arthritis (JIA) for 12 weeks

Trial Profile

A multicentre, open, uncontrolled phase IIIb study to evaluate the efficacy and safety of Etanercept 0.8 mg/kg body weight (bw) given once weekly to patients with polyarticular-course juvenile idiopathic arthritis (JIA) for 12 weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Etanercept (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top